News & Events

After we published our list on the top 15 venture deals of H1 2012, the folks at Celladon dropped us a note to say that they did bank the full $53 million venture round in the period, which includes a $10 million extension, rather than the tranche we reported. So Thomson Reuters is updating its records, and so are we. 

Celladon now has boasting rights to the third highest biotech round of the first half. This new money includes contributions from a new group of investors: Pfizer Venture Investments, Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors and GBS Venture Partners. And much of the cash is being earmarked for their Mydicar program for heart failure.